PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Trial Details

NCT ID
NCT06673017
Phase
PHASE1
Sponsor
PanTher Therapeutics
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • PTM-101
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Lake Success, New York, United States|40.77066,-73.71763
  • Dallas, Texas, United States|32.78306,-96.80667
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Imaging consistent with primary borderline resectable or locally advanced PDAC. PDAC may be confirmed by histology/cytology either at study-mandate…
  • Indicated for laparoscopy
  • No prior therapy of any kind for PDAC
  • Acceptable laboratory values

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →